As a pharmaceutical manufacturing company of the Nipro Group, we have been developing our business to ensure a stable supply of drugs based on the concept of compliance that places the highest priority on quality and forms the foundation of compliance. Currently, we are commissioning contract manufacturing of drugs from numerous pharmaceutical companies, both domestically and abroad, and our contract manufacturing results are among the top-ranked in Japan.

In 2024, we established a new injectable plant in Shiga Prefecture (Omi Plant) at 11 domestic sites and one overseas site (Vietnam), for a total of 12 sites (including subsidiaries). In addition to the production of a wide variety of drug forms, we have a system capable of responding to a wide range of production scales, and we will strive to further meet the demand of pharmaceutical companies and ensure a stable supply.
Additionally, the establishment of a kit product manufacturing line developed in cooperation with Nipro Co., Ltd., we have also established a dedicated manufacturing facility for high-potency pharmacological and antibiotic products. We intend to contribute to the manufacture of drugs in Japan by continuing to actively invest in facilities and equipment that meet the needs of the market.

In addition, each base is gradually expanding its supply capacity, and at the same time, by establishing a parallel production system for the same formulation between the bases, we will also respond to the Business Continuity Planning (BCP).
On the other hand, the concept of pharmaceutical quality continues to evolve on a daily basis, necessitating the establishment of more robust and reliable systems than ever before. Based on the Quality Policy, Quality Goals, and Quality Planning, we are enhancing the quality assurance system by using IT system to improve quality awareness, periodic internal audits, manufacturing implementation systems (MES), and the establishment of a quality assurance system backed by records and data from the Quality Control System (LIMS).
In 2024, we established Doshomachi Analysis Center to support analytical work at our plants and to establish more advanced analytical techniques. In addition, we have established a dedicated quality testing facility at the Saitama Plant, which functions to train test procedures and skills, to expand the analytical capacity and increase the level of test personnel.

With the primary idea of providing patients and healthcare professionals with drugs that can be used with confidence, we aim to create an organizational quality culture for the realization of this, while also enhancing the awareness of compliance among all employees to improve the quality.
Medicines are closely related to people's health and life. Each of our employees has a thorough sense of responsibility and mission in producing pharmaceuticals, and we are striving to become a world-class pharmaceutical manufacturer. We would like to express our gratitude to all of you for your patronage and ask for your continued support and encouragement of Nipro Pharma as your partner.